BDR Pharmaceuticals on Tuesday launched an oral solution in 32mg/mL designed for the management of prostate cancer. According to a press statement, BDENZA will be available at Rs. 27,000 for 150mL.
“This innovative formulation marks a significant step forward in providing an effective dosage form, with lesser side effects in comparison to existing oral dosage forms of Enzalutamide. The Dose reduction owing to tolerability of the product by patients is a big advantage of this oral solution, as dose regimen can be adjusted based on the volume of consumption. This flexibility is absent in existing oral dosage forms of Enzalutamide,” the company said in a statement.
Recognizing the significant challenge faced by Geriatric patients/ Old patients BDR Pharmaceuticals introduced affordable alternative medication formulation, it claimed.
“Changing how we treat prostate cancer, BDENZA ORAL SOLUTION brings a mix of benefits to make things better for patients. It gives a strong 160mg dose in just one small 5ml serving, so there’s less hassle associated with lots of pills. Unlike fixed-dose tablets, doctors can adjust the dosage to fit each patient better. This oral solution is gentle on the stomach, avoiding issues like nausea. Plus, it is sugar-free and tastes good, making it easier for patients, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent,” Dr. Aravind Badiger Director, Technical Formulation said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.